The latest developments aim to support customers with a wide range of assay customization options, from simple to complex and validated multiplex assays, while further improving the user experience. This is also likely to boost QIAGEN's Life Science business area. Image Source: Zacks Investment Research Additional enhancements of the GeneGlobe research platform have been launched recently or are currently in development, including more user-friendly design pages that simplify product selection and a new too ...

Venlo, the Netherlands, June 06, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a decision to discontinue the NeuMoDx 96 and 288 Molecular Systems in light of the market development trends for these product lines following the COVID-19 pandemic and changing customer needs for integrated PCR-based clinical molecular testing systems. QIAGEN understands the impact of this decision on its customers and will continue to provide support for existing NeuMoDx users durin ...

Venlo, the Netherlands, June 06, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a decision to discontinue the NeuMoDx 96 and 288 Molecular Systems in light of the market development trends for these product lines following the COVID-19 pandemic and changing customer needs for integrated PCR-based clinical molecular testing systems. "We recognize the valuable role that the NeuMoDx 96 and 288 Molecular Systems have played in many laboratories, especially in the glo ...

Genetic research is moving fast, and new target genes are rapidly evolving that are not covered by standard or pre-designed assays. To keep pace and close the need gap, the new digital PCR Custom Assay Design Tool has been developed as an interface on the GeneGlobe platform. It enables customers to design and order assays for use on QIAGEN's digital PCR platform QIAcuity outside of QIAGEN's comprehensive catalog of over 200 wet-lab validated assays for copy number variations profiling in translational cance ...

QIAGEN N.V. (QGEN) announced the launch of QIAstat-Dx Gastrointestinal Panel 2 in the United States following the recent FDA clearance of the syndromic test for use in clinical settings. The launch marks a significant step forward in improving the accuracy and efficiency of gastrointestinal (GI) infection diagnosis. The latest development from QIAGEN addresses the major challenges of the diagnosis of overlapping symptoms and laborious testing methods in treating GI infections. This should also strengthen th ...

QIAGEN N.V. (QGEN) recently announced the launch of its QIAseq Multimodal DNA/RNA Lib Kit. The new kit enables seamless preparation of DNA and RNA libraries for next-generation sequencing (NGS), such as whole genome sequencing (WGS) and whole transcriptome sequencing (WTS), as well as downstream target enrichment based on hybrid capture from a single sample. News in Detail The introduction of the QIAseq Multimodal DNA/RNA Lib Kit addresses a direct need in the scientific community for a more efficient way t ...

Germantown, Maryland, and Venlo, the Netherlands, June 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Gastrointestinal Panel 2 in the United States. The launch comes after the recent clearance of the syndromic test for clinical use by the U.S. Food and Drug Administration (FDA) and marks a significant step forward in improving the accuracy and efficiency of gastrointestinal (GI) infection diagnosis. The QIAstat-Dx Gastrointestinal ...

Germantown, Maryland, and Venlo, the Netherlands, June 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Gastrointestinal Panel 2 in the United States. The launch comes after the recent clearance of the syndromic test for clinical use by the U.S. Food and Drug Administration (FDA) and marks a significant step forward in improving the accuracy and efficiency of gastrointestinal (GI) infection diagnosis. The QIAstat-Dx Gastrointestinal ...

Venlo, the Netherlands, and Salt Lake City, Utah, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. This next-generation sequencing (NGS) test aims to support research into personalized medicine in multiple solid tumor types, including ovarian cancer and is expected to enhance decentralized testing capac ...

A month has gone by since the last earnings report for Qiagen (QGEN) . Shares have added about 1.6% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Qiagen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. QIAGEN Q1 Earnings and Revenues Top, Margins Rise QIAGEN N.V ...